Abstract Details
Robert Hoepner
PRESENTER |
Robert Hoepner has nothing to disclose. |
No disclosure on file | |
No disclosure on file | |
Anke Salmen (St. Josef-Hospital, Ruhr -University Bochum) | The institution of Anke Salmen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neuraxpharm. Anke Salmen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Anke Salmen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Anke Salmen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neuraxpharm. Anke Salmen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. The institution of Anke Salmen has received research support from Regional association of the German MS Society (DMSG Landesverband NRW). |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
Helmut Butzkueven, MD, MBBS (Alfred Hospital) | Dr. Butzkueven has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Oxford Health Policy Forum. The institution of Dr. Butzkueven has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. The institution of Dr. Butzkueven has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck. The institution of Dr. Butzkueven has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. The institution of Dr. Butzkueven has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Butzkueven has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for MSBase . The institution of Dr. Butzkueven has received research support from NHMRC. The institution of Dr. Butzkueven has received research support from Biogen. The institution of Dr. Butzkueven has received research support from Roche. The institution of Dr. Butzkueven has received research support from Novartis. |
Ralf Gold, MD (Neurologische Universitaetsklinik) | Dr. Gold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen . Dr. Gold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Gold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer Vital. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Pharamaceuticals. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Gold has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for SAGE Publishers. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Novartis. Dr. Gold has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Biogen. The institution of Dr. Gold has received research support from Novartis. The institution of Dr. Gold has received research support from Biogen. |
Fred Luhder (IMSF) | No disclosure on file |
Andrew Chan | The institution of Andrew Chan has received research support from UCB. The institution of Andrew Chan has received research support from Biogen. The institution of Andrew Chan has received research support from Sanofi Genzyme. |